- Home
- » Tags
- » Aminoglutethimide
Top View
- PHARMACOLOGY: Core Concepts and Learning Objectives
- Trilostane Vetoryl® Is Another Name for This Medication
- Combination Hormonal Therapy Involving Aromatase Inhibitors in the Management of Women with Breast Cancer
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- Assessment Report: Ketoconazole
- Banned Substances
- 202107Orig1s000
- Examples of Prohibited and Permitted Substances And
- LPGA Prohibited Substances List
- Effects of Orchiectomy, Alone Or in Combination with Testosterone, and Cyproterone Acetate on Exocrine Pancreatic Carcinogenesis in Rats and Hamsters
- Pregnenolone Biosynthesis in C6-2B Glioma Cell Mitochondria
- Aminoglutethimide: a 'Side-Effect' Turned to Therapeutic Advantage
- Effect of Aminoglutethimide on Blood Pressure and Steroid Secretion in Patients with Low Renin Essential Hypertension
- DRUG NAME: Megestrol
- Tamoxifen Versus Aminoglutethimide Versus Combined Tamoxifen and Aminoglutethimide in the Treatment of Advanced Breast Carcinoma1
- Pretest Pharmacology
- Treatment of Testosterone-Induced Gynecomastia with the Aromatase Inhibitor, Anastrozole
- Customs Tariff - Schedule Xxi - 1
- Aminoglutethimide
- Combination Hormonal Therapy Involving Aromatase Inhibitors in the Management of Women with Breast Cancer
- Examples of Prohibited Substances & Methods
- Androgen Receptor Signaling Inhibitors: Post-Chemotherapy, Pre-Chemotherapy and Now in Castration-Sensitive Prostate Cancer
- Medical Management of Cushing Disease
- Clinical and Endocrineeffectsof the Oral Aromataseinhibitor Vorozolein
- Profound Suppression of Plasma Estrogens by Megestrol Acetate in Postmenopausal Breast Cancer Patients’
- (12) Patent Application Publication (10) Pub. No.: US 2002/0004065 A1 Kanios (43) Pub
- NFL List of Prohibited Substances I. ANABOLIC AGENTS
- Harmonized Tariff Schedule of the United States (2006) (Rev
- WADA 2018 Prohibited List
- Multicentre Cross Over Study of Aminoglutethimide and Trilostane in Advanced Postmenopausal Breast Cancer
- Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
- Effects of Aromatase Inhibitors, Aminoglutethimide, and 4- Hydroxyandrostenedione on Cyclic Rats and Rats with 7,12- Dimethylbenz(A)Anthracene-Induced Mammary Tumors1
- The Influence of Aminoglutethimide and Its Analogue Rogletimide on Peripheral Aromatisation in Breast Cancer
- Steroidogenesis Enzyme Inhibitors in Cushing's Syndrome
- 103097 Drug Therapy Corticosteroid Therapy in Severe
- Aminoglutethimide (Cytadren®) | UPMC Hillman Cancer Center
- 2020 Prohibited List
- Supplementary Table 1: List of Drugs and Their Binding Energies to ACE and ACE2
- C:\LIB\ALDRICH\ Library Title: Fibras Library Type: User Number of Entries: 376 Library Data Point Spacing: 8.0 Library Range: 450.0 to 4000.0 Cm-1
- Tamoxifen, Aminoglutethimide and Danazol: Effect of Therapy on Hormones in Post-Menopausal Patients with Breast Cancer R
- Aminoglutethimide Tablets USP
- LPGA Prohibited Substances List
- Tamoxifen and Aminoglutethimide Compared with Responses Obtained with Tamoxifen Alone and Skyler JS, Lasky IA, Skyler DL, Robertson EG, Mintz DH
- The Effects of Treatment with Prasterone (Dhea) on Circulating Hormones, Body Composition and Muscle Strength in Men and Women